Apr 26, 2016

Posted by in Biotech Stocks | 0 Comments

Stock News: Viking Therapeutics Inc (NASDAQ:VKTX), Repros Therapeutics Inc (NASDAQ:RPRX), Threshold Pharmaceuticals Inc (NASDAQ:THLD)

Stock News: Viking Therapeutics Inc (NASDAQ:VKTX), Repros Therapeutics Inc (NASDAQ:RPRX), Threshold Pharmaceuticals Inc (NASDAQ:THLD)

Viking Therapeutics Inc (NASDAQ:VKTX) surged +14.63% and ended at $1.68. The total traded volume was 1.93 million shares and market capitalization arrived at $33.06 million. The stock has a 52-week high price of $10.23 and its 52-week low was recorded at $1.06, while during last trade its minimum price was $1.47 and it gained the highest price of $1.80.

Viking Therapeutics Inc (NASDAQ:VKTX) on April 13, 2016 announced the closing of its previously-announced underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of $1.25 per share of common stock and related warrant.  The warrants have an exercise price of $1.50 per share of common stock, are immediately exercisable and will expire on April 13, 2021.

Viking granted the underwriters a 45-day option to purchase up to an additional 1,125,000 shares of its common stock and/or warrants to purchase up to an additional 1,125,000 shares of its common stock to cover over-allotments, if any.  Viking also announced that the underwriters partially exercised the over-allotment option for warrants to purchase an additional 1,125,000 shares of its common stock at a public offering price of $0.01 per warrant.

Repros Therapeutics Inc (NASDAQ:RPRX) reported the decrease of -8.27% to close at $2.55 with the overall traded volume of 1.91 million shares. Its market capitalization on last close reached to $60.49 million. Its beta value stands at -0.12 times. The company has the total of 24.32 million outstanding shares. Its intraday-low price was $2.52 and its hit its day’s highest price at $2.78.

Repros Therapeutics Inc (NASDAQ:RPRX) on April 12, 2016 eported that vaginal administration of Proellex® at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.

Normal menstrual blood loss in a menstrual cycle is approximately 35 mL. Woman experiencing blood loss of >80 mL are considered to suffer from menorrhagia or excessive menstrual bleeding. In this small Phase 2b study, 13, 15 and 14 women with confirmed uterine fibroids were enrolled in the 6mg, 12mg and placebo arms, respectively. At baseline, the mean amount of blood lost for one menstrual cycle was 255 mL, 274 mL and 238 mL for each arm, respectively. The blood loss ranged from a low of 94 mL to a high of 654 mL. The most severe menstrual bleeding at baseline was observed in the 12 mg group. Blood loss was determined by collecting all sanitary products used from an individual and then an alkaline hematin assay was performed to estimate the actual amount of blood collected in the pads.

When a sufficient concentration of Proellex® is achieved in circulation, amenorrhea (cessation of menses) is achieved. Just over half, 52%, of Proellex®-treated subjects became amenorrheic with no evidence of a dose effect. All subjects treated with Placebo continued to menstruate throughout the 18 week dosing period. The p-value for this comparison is 0.0011.  Bleeding diaries consistently report a statistically significant difference in the number of days of bleeding and bleeding intensity between those treated with Proellex® and Placebo.

Bleeding was also evaluated by PBAC (Pictorial Blood Assessment Chart).  Subjects tallied sanitary product usage and stain size as guided by the chart.  Proellex®-treated subjects reported a median 100% reduction in PBAC scores while Placebo-treated subjects reported a 25.4% reduction, further supporting the treatment affect associated with bleeding (p=0.0033).

Along with changes in menstrual patterns, fibroids measured by MRI were reduced in volume in the Proellex®-treated arms by 18% while the Placebo group showed continued increase in size, p= 0.0437.

Threshold Pharmaceuticals Inc (NASDAQ:THLD) moved up +6.06% to settle at $0.462. Its total traded volume during last trading session was 1.88 million shares. The overall market worth of this company is about $32.66 million. The 52 week range of the stock remained $0.21 – $5.28, while its day’s lowest price was $0.42 and its hit its day’s highest price at $0.48. The beta of this stock currently stands at 3.91.

Threshold Pharmaceuticals Inc (NASDAQ:THLD) on March 21, 2016 announced the appointment of Stewart M. Kroll as Chief Operating Officer. Mr. Kroll will serve as the Company’s principal operating officer, will continue to report to Barry Selick, CEO, and will be responsible for the design and execution of Threshold’s clinical development programs.

Mr. Kroll served as Threshold’s Senior Vice President, Clinical Operations and Biostatistics since May 2011 and as Threshold’s Vice President, Biostatistics and Clinical Operations since March 2007. Mr. Kroll joined the company as Director, Biostatistics in January 2005. Prior to joining Threshold, Mr. Kroll served as Senior Director of Biostatistics at Corixa Corporation and held positions of increasing responsibility, most recently as Director of Biostatistics at Coulter Pharmaceuticals.

 

Comments are closed.